SOTYKTU JAK Inhibitor for Psoriasis Treatment SOTYKTU (deucravacitinib) belongs to a class of medications known as Janus kinase (JAK) inhibitors. JAK inhibitors have demonstrated significant advancements in the treatment of various immune-mediated conditions, particularly psoriasis. SOTYKTU, as a JAK inhibitor, offers a targeted and effective approach for managing moderate-to-severe plaque psoriasis in adults. it is… Read More
